Boston Scientific Corporation (BSX)
| Previous close | 37.93 |
| Open | 38.36 |
| Bid | 0.00 x 1000 |
| Ask | 0.00 x 2900 |
| Day's range | 38.22 - 39.71 |
| 52-week range | 24.10 - 42.37 |
| Volume | 12,809,414 |
| Avg. volume | 11,020,521 |
| Market cap | 55.997B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | 15.18 |
| EPS (TTM) | N/A |
| Earnings date | 27 Apr 2021 - 03 May 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 43.36 |
- Zacks
Boston Scientific (BSX) Down 2.1% Since Last Earnings Report: Can It Rebound?
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks
Boston Scientific (BSX) Buys Lumenis to Expand in Urology
The transaction is expected to remain immaterial to Boston Scientific's (BSX) 2021 adjusted earnings per share.
- PR Newswire
Boston Scientific Announces Agreement To Acquire Lumenis LTD. Surgical Business From Baring Private Equity Asia
Boston Scientific (NYSE: BSX) today announced that it has entered into a definitive agreement with an affiliate of Baring Private Equity Asia (BPEA) to acquire the global surgical business of Lumenis LTD., a privately-held company that develops and commercializes energy-based medical solutions, for an upfront cash payment of $1.07 billion, subject to closing adjustments. BPEA will retain ownership of the Lumenis global aesthetics and ophthalmology businesses. With 2021 net sales anticipated to be approximately $200 million, the Lumenis surgical business includes premier laser systems, fibers and accessories used for urology and otolaryngology procedures. Foundational to its urology portfolio is the proprietary MOSES™ technology, which has demonstrated differentiated clinical outcomes and efficiency in the management of patients with kidney stones.
